Clinical trials: Locally Advanced Lung Carcinoma
Non Small Cell Lung Cancer
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation…
- Trial name
- NCT06300177
- Testing
- D-1553 Tablet, Docetaxel injection
- Where
- 86 sites in China
- Volunteers
- 522 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer
A Study of DS-3939a in Participants With Solid Tumors
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
- Conditions
- Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07739966
- Testing
- DS-3939a, Pembrolizumab, Carboplatin
- Where
- 76 sites in United States, Argentina and 11 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
NSCLC
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Trial name
- NCT05492045
- Testing
- D-1553, Other
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- InventisBio Co., Ltd
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT04984811
- Testing
- efineptakin alfa, Atezolizumab
- Where
- 22 sites in United States
- Volunteers
- 33 people
- Sponsor
- NeoImmuneTech
Non-small Cell Lung Cancer
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the anti-tumor activity of LY2181308 in combination with docetaxel compared to docetaxel alone in participants with non-small cell lung cancer who were previously treated with first line…
- Trial name
- NCT01107444
- Testing
- Docetaxel, LY2181308
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes the cancer treatment more effective in patients with locally advanced or metastatic non-small cell lung cancer
- Trial name
- ATTRACT-2 (NCT00738387)
- Testing
- ASA404, docetaxel
- Where
- 162 sites in United States, Belgium and 8 more
- Volunteers
- 900 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR…
- Trial name
- NCT03866499
- Testing
- BPI-7711, Gefitinib
- Where
- 3 sites in China
- Volunteers
- 369 people
- Sponsor
- Beta Pharma Shanghai
Solid Tumor, Non-Small-Cell Lung Cancer
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT07094204
- Testing
- ASP5834, panitumumab
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 404 people
- Sponsor
- Astellas Pharma Inc
Non-Small Cell Lung Cancer With EGFR Mutation
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of CFT8919 capsules in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying…
- Trial name
- NCT06641609
- Testing
- Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8919 capsule
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Lung Cancer
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in PD-L1 negative, locally advanced or metastatic…
- Trial name
- NCT05690945
- Testing
- QL1706, Tilesizumab
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
- Trial name
- NCT06010329
- Testing
- Sutetinib Maleate Capsule
- Where
- 24 sites in United States, China
- Volunteers
- 66 people
- Sponsor
- Teligene US
Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1.
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT06758401
- Testing
- Sigvotatug Vedotin, Pembrolizumab
- Where
- 389 sites in United States, Argentina and 29 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
To assess the efficacy of single-agent osimertinib in relation to EGFR T790M mutant allele fraction (AF) in a real-world setting.
- Trial name
- NCT03219970
- Testing
- Osimertinib
- Where
- 4 sites in China
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
The primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in subjects with locally advanced or metastatic…
- Trial name
- ATTENTION (NCT01377376)
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a multicenter, open-label, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic /pharmacodynamic characteristics of SIM0518 in trial participants with ALK-positive or ROS1-positive…
- Trial name
- NCT07912268
- Testing
- SIM0518, SIM0518+Bupropion, SIM0518+Midazolam
- Where
- 8 sites in China
- Volunteers
- 270 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Non-small Cell Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants…
- Trial name
- DESTINY-Lung06 (NCT06899126)
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed
- Where
- 246 sites in United States, Argentina and 22 more
- Volunteers
- 686 people
- Sponsor
- Daiichi Sankyo